Skip to content

Small-airway disease and emphysema

TL;DR — Persistent airflow obstruction emerges from variable combinations of small-airway narrowing/obliteration, emphysematous loss of elastic recoil, mucus dysfunction and vascular change (Christenson 2022, PMID 35533707). Small conducting airways can be extensively diseased before routine spirometry crosses the COPD threshold; emphysema may likewise be visible on CT before obstruction (Verleden 2024, PMID 38055196). Expiratory flow limitation produces gas trapping and dynamic hyperinflation, tightly linking anatomy to exertional dyspnea (Welling 2023, PMID 37039738). CT quantifies structure but cannot by itself distinguish active mechanism from irreversible damage. Repair biology is a frontier: animal reversal signals have not yet established human regeneration (Hadzic 2023, PMID 37884305).

Structural compartments

Compartment Lesion Functional result
Small airways <2 mm Wall thickening, fibrosis, loss, mucus Increased peripheral resistance and gas trapping
Alveoli Septal destruction Reduced recoil and gas-exchange surface
Large airways Mucus, gland enlargement, wall change Cough, sputum and plugs
Pulmonary vessels Pruning/remodeling Diffusion and hemodynamic effects
Respiratory muscles Adverse geometry under hyperinflation Higher work and dyspnea

Small-airway disease

Small airways are the major site of resistance increase in COPD. Pathology includes luminal mucus, inflammatory infiltration, peribronchiolar fibrosis and disappearance of terminal bronchioles.

Pre-COPD imaging/pathology work shows small-airway abnormality in people with emphysema but preserved conventional spirometric ratio, supporting a long silent phase (Verleden 2024, PMID 38055196).

Measurement What it captures Limitation
Spirometry Integrated expiratory flow Insensitive to early regional disease
Lung volumes Gas trapping/hyperinflation Not anatomically specific
Oscillometry Frequency-dependent mechanics Thresholds and outcome utility unsettled
Expiratory CT Air trapping Effort and vascular disease confound
Parametric response mapping Voxelwise inspiratory/expiratory patterns Algorithm/scan dependence
Histology/micro-CT Direct airway loss Invasive/ex vivo samples

Emphysema

Emphysema is permanent airspace enlargement with alveolar-wall destruction. Centrilobular, panlobular and paraseptal patterns carry different exposure/genetic associations but frequently coexist.

Pattern Typical distribution/association Caution
Centrilobular Upper-lobe, smoking-associated Not exclusive to smoking
Panlobular Diffuse/lower-lobe, severe AATD Distribution is not a genetic test
Paraseptal Subpleural Pneumothorax association
Bullous Large airspaces Distinguish compressive bulla from diffuse disease

Machine-learning analysis identifies CT emphysema subtypes, but clustering reproducibility and therapeutic implications remain under study (Angelini 2023, PMID 37268414).

Protease, oxidative and immune injury

The protease–antiprotease model is validated most clearly by severe AATD; tobacco and inflammatory cells add protease burden and oxidant-mediated loss of antiprotease function (Stockley 2014, PMID 24507836). Adaptive immune contributions include lymphoid follicles and T/B-cell responses, although whether these perpetuate injury after exposure cessation is unresolved (Kheradmand 2023, PMID 36201635).

Spatial transcriptomics has identified an emphysema-associated lymphoid-follicle B-cell signature, providing anatomical resolution but not yet a treatment rule (Rojas-Quintero 2024, PMID 37934672).

Gas exchange and hyperinflation

Loss of recoil narrows airways during expiration. Incomplete emptying raises end-expiratory lung volume; exercise shortens expiratory time and magnifies dynamic hyperinflation (Welling 2023, PMID 37039738).

Consequence Mechanistic link
Exertional dyspnea Inspiratory reserve shrinks toward total lung capacity
Reduced tidal-volume expansion Mechanical ceiling
Increased work Threshold and elastic loads
V/Q mismatch Regional airway and alveolar injury
Low DLCO Alveolar/vascular surface loss, anemia also matters

Mucus plugs and chronic bronchitis

Mucus hypersecretion, dehydration, impaired cilia and airway narrowing produce plugs. Chronic bronchitis is defined clinically by cough/sputum duration and is not synonymous with CT airway disease. Mucus can contribute to exacerbation and regional gas trapping.

Repair and regeneration

Animal models recapitulate selected injuries, not the complete human syndrome (Upadhyay 2023, PMID 37183431). FGF10 reversed smoke/elastase-associated emphysema and pulmonary hypertension in mice, a mechanistic proof-of-concept rather than evidence for human therapy (Hadzic 2023, PMID 37884305).

Quantitative structural evidence

Observation Scale/result Inference and limit
Terminal-airway loss GOLD 4 explants had 72–89% fewer terminal bronchioles and 81–99.7% less total terminal-bronchiole cross-sectional area than controls (McDonough 2011, PMID 22029978). Loss can precede visible emphysema, but end-stage explants are selected.
CT-visible mucus In 4,363 COPDGene participants, mucus plugs involved 0, 1–2 and ≥3 segments in 59.3%, 21.8% and 18.9%; corresponding mortality was 34.0%, 46.7% and 54.1% over median 9.5 years (Diaz 2023, PMID 37210745). Plug burden is prognostic after adjustment, not yet a validated treatment-selection biomarker.
Molecular mucus SPIROMICS linked airway MUC5AC/MUC5B concentrations to COPD initiation and progression (Radicioni 2021, PMID 34058148). Sputum concentration, CT plugging and obstruction overlap but are not interchangeable.
Hyperinflation Static and dynamic hyperinflation integrate loss of recoil, expiratory flow limitation and breathing pattern (Welling 2023, PMID 37039738). Similar FEV1 can conceal different mechanical constraints.
CT heterogeneity Machine-derived emphysema subtypes capture spatial anatomy beyond percent low attenuation (Angelini 2023, PMID 37268414). Reproducibility and treatment prediction need prospective testing.

Mechanistic sequence and competing models

  1. Repeated epithelial injury disrupts barrier and mucociliary function (Aghapour 2018, PMID 28933915).
  2. Mucus, peribronchiolar fibrosis and inflammation narrow or obliterate terminal bronchioles before extensive parenchymal destruction (McDonough 2011, PMID 22029978; Verleden 2024, PMID 38055196).
  3. Protease–antiprotease imbalance is causally anchored by severe AAT deficiency, but non-AATD emphysema also involves oxidative stress, cell death and adaptive immunity (Stockley 2014, PMID 24507836; Kheradmand 2023, PMID 36201635).
  4. Spatial transcriptomics identifies immune niches adjacent to remodeling but cannot determine whether they drive or respond to destruction (Rojas-Quintero 2024, PMID 37934672).
  5. Experimental FGF10 can reverse emphysema-like injury in mice; translation must confront delivery, fibrosis and oncogenic risk (Hadzic 2023, PMID 37884305).

The airway-first and parenchyma-first models need not be mutually exclusive. AATD, tobacco injury and chronic-bronchitic mucus can weight the sequence differently. CT and MRI are therefore regional phenotyping tools rather than a single severity ladder (Elbehairy 2024, PMID 38548292).

Structural treatment experiment

In TRANSFORM, 55.4% assigned to Zephyr valves versus 6.5% receiving standard care achieved ≥12% FEV1 improvement at 3 months; at 6 months the between-group differences were −700 mL residual volume, +78.7 m six-minute walk distance and −6.5 SGRQ points, with pneumothorax in 29.2% (Kemp 2017, PMID 28885054). This supports hyperinflation as a causal contributor in anatomically selected disease while showing why collateral ventilation is treatment-predictive.

Measurement concordance gaps

Measure Dominant signal Important blind spot
Spirometry Integrated expiratory flow limitation Insensitive to regional early terminal-airway loss
Plethysmography Gas trapping and hyperinflation Does not localize the responsible compartment
DLCO Gas-transfer surface and vascular contribution Anemia, effort and pulmonary vascular disease confound
Inspiratory/expiratory CT Emphysema, airway wall, gas trapping and plugs Radiation, reconstruction and inspiratory-volume dependence
Hyperpolarized-gas MRI Regional ventilation and diffusion Limited availability and multicenter standardization
Micro-CT/histology Terminal-airway anatomy Explant/autopsy selection prevents routine longitudinal use

No single measurement adjudicates the sequence of airway loss, emphysema and vascular remodeling. Concordant multimodal change is more compelling than a cross-sectional correlation, but treatment prediction remains the required standard (Elbehairy 2024, PMID 38548292; Christenson 2023, PMID 37353326).

Human airway repair and remodeling at cellular resolution

Human respiratory bronchioles contain respiratory-airway secretory cells that act as unidirectional progenitors for alveolar type-2 cells through Notch/Wnt-regulated differentiation; in COPD these cells and their alveolar descendants show altered transcriptional states, a human-specific repair axis not represented faithfully in mice (Basil 2022, PMID 35355013). In 262 lung samples from 34 ex-smokers, a single-cell and micro-CT atlas found terminal-bronchiole luminal narrowing and loss of elastin-containing alveolar attachments before microscopic emphysema; macrophages and neutrophils localized to attachment loss while adaptive cells tracked wall remodeling (Booth 2023, PMID 37406359). At the organ scale, COPDGene airway-tree analysis in 7,641 participants linked less luminal tapering independently to lower FEV1, shorter walk distance, faster decline, more exacerbations (IRR 0.78 per unit, 95% CI 0.73–0.83) and mortality (HR 0.79, 0.72–0.86) (Bodduluri 2024, PMID 39326917). Whether tapering is a causal lesion, a repair failure or a geometric summary of accumulated injury remains unresolved.

Longitudinal CT strengthens the case that airway loss is not merely cross-sectional severity. Over three years, total airway count fell in ex-smokers with COPD even when FEV1 did not, and baseline wall thickness predicted worsening count (Wyszkiewicz 2023, PMID 37395048). In a Chinese early-COPD cohort, CT-visible airway count was 31% lower in GOLD I and 51% lower in GOLD II than controls and independently predicted longitudinal FEV1 and ratio decline over mean 5.5 years (Wu 2021, PMID 34984001). Scanner/reconstruction dependence and inability to visualize terminal bronchioles still prevent simple clinical thresholds.

In explanted lungs from 11 people with severe COPD and three controls, CT parametric-response mapping classified functional small-airway disease in regions showing terminal-bronchiole loss, reduced luminal area and complete obstruction, whereas the emphysema class tracked airspace enlargement and alveolar-surface loss (Vasilescu 2019, PMID 30794432). This is unusually direct structure–image validation, but the small end-stage surgical sample limits extrapolation to early disease.

Five-year paired CT in 1,495 COPDGene participants separated emphysema-dominant, functional-small-airway-dominant and a small-airway-transition topology; the transition pattern was concentrated in at-risk people with normal spirometry and showed the fastest local progression to emphysema (Wang 2024, PMID 37661554). The proposed precursor sequence is longitudinally coherent, but an imaging-defined transition state is not yet evidence that intervention can prevent emphysema.

Open questions

  • Which early small-airway measurement predicts progression better than spirometry? (Verleden 2024, PMID 38055196)
  • Are CT emphysema clusters stable and treatment-predictive? (Angelini 2023, PMID 37268414)
  • Which immune structures maintain disease after smoking cessation? (Rojas-Quintero 2024, PMID 37934672)
  • Can human alveolar repair be activated without fibrosis or cancer? (Hadzic 2023, PMID 37884305)
  • How should airway loss and emphysema be combined into procedural selection? (Elbehairy 2024, PMID 38548292)

References

  1. Christenson SA, et al. Chronic obstructive pulmonary disease. Lancet. 2022. PMID 35533707
  2. Verleden SE, et al. Small airway disease in pre-COPD with emphysema. Am J Respir Crit Care Med. 2024. PMID 38055196
  3. Welling JBA, et al. Dynamics of hyperinflation. Respirology. 2023. PMID 37039738
  4. Angelini ED, et al. Pulmonary emphysema subtypes defined by unsupervised machine learning on CT. Thorax. 2023. PMID 37268414
  5. Kheradmand F, et al. Contribution of adaptive immunity to human COPD and experimental emphysema. Physiol Rev. 2023. PMID 36201635
  6. Rojas-Quintero J, et al. Spatial transcriptomics resolves an emphysema-specific lymphoid-follicle B-cell signature. Am J Respir Crit Care Med. 2024. PMID 37934672
  7. Hadzic S, et al. FGF10 reverses smoke- and elastase-induced emphysema in mice. Eur Respir J. 2023. PMID 37884305
  8. Upadhyay P, et al. Animal models and mechanisms of tobacco-smoke-induced COPD. J Toxicol Environ Health B Crit Rev. 2023. PMID 37183431
  9. Stockley RA. Alpha-1-antitrypsin review. Clin Chest Med. 2014. PMID 24507836
  10. Elbehairy AF, et al. Advances in COPD imaging using CT and MRI. Eur Respir J. 2024. PMID 38548292
  11. McDonough JE, et al. Small-airway obstruction and emphysema in COPD. N Engl J Med. 2011. PMID 22029978
  12. Diaz AA, et al. Airway-occluding mucus plugs and mortality in COPD. JAMA. 2023. PMID 37210745
  13. Radicioni G, et al. Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of COPD. Lancet Respir Med. 2021. PMID 34058148
  14. Aghapour M, et al. Cigarette-smoke epithelial barrier dysfunction. Am J Respir Cell Mol Biol. 2018. PMID 28933915
  15. Kemp SV, et al. TRANSFORM Zephyr-valve trial. Am J Respir Crit Care Med. 2017. PMID 28885054
  16. Christenson SA. COPD phenotyping. Respir Care. 2023. PMID 37353326
  17. Basil MC, et al. Human distal airways contain a multipotent secretory cell that can regenerate alveoli. Nature. 2022. PMID 35355013
  18. Booth S, et al. A single-cell atlas of small-airway disease in COPD. Am J Respir Crit Care Med. 2023. PMID 37406359
  19. Bodduluri S, et al. Airway tapering in COPD. Eur Respir J. 2024. PMID 39326917
  20. Wyszkiewicz PV, et al. Reduced total airway count and airway-wall tapering after three years in ex-smokers. COPD. 2023. PMID 37395048
  21. Wu F, et al. Total airway count and lung-function decline in early COPD. Int J Chron Obstruct Pulmon Dis. 2021. PMID 34984001
  22. Vasilescu DM, et al. Noninvasive imaging biomarker identifies small-airway damage in severe COPD. Am J Respir Crit Care Med. 2019. PMID 30794432
  23. Wang JM, et al. Topologic parametric response mapping identifies tissue subtypes associated with emphysema progression. Acad Radiol. 2024. PMID 37661554